Huma appoints Paul Schultz as VP Global Pharma Partnerships, SaMD

Did you know that a significant number of patients fail to follow their prescribed medication regimen, even for chronic illnesses? According to a 2018 McKinsey publication on the potential for digital solutions to improve adherence and persistence rates in biopharma, up to one-third of patients do not fill their initial prescription, and of those who do, 50-60% miss doses, take the wrong doses, or drop off treatment within the first year.

This presents a major opportunity for digital innovation to improve patient outcomes and drive business success for pharmaceutical companies. While there has been some progress in developing digital solutions to support patient adherence and engagement, the market is still relatively early and many new therapies are launching without a comprehensive digital ecosystem.

However, the potential rewards are significant. The global market for digital health in pharma is projected to reach $33 billion by 2024, up from $7.1 billion in 2021. As with any large market, there will be multiple players that establish themselves within the pharma digital health ecosystem, each with their own differentiation and market position. Just as Google, Amazon, and Microsoft dominate the public cloud market, we can expect to see key players emerge in the pharma digital health space.

As someone who has spent their entire career in digital health for life sciences, I am excited to see this early market grow to its true potential. That's why I am thrilled to announce that I have joined Huma as VP Global Pharma Partnerships, SaMD. With Huma most recently receiving the world’s first and only multi-condition EU MDR Class IIb regulatory approval for its configurable SaMD disease management platform, Huma is well positioned to be a leader in this space.?

I look forward to working with our partners to shape the future of digital health in biopharma and help each patient live their life to the fullest.

About Paul Schultz

Paul recently joined Huma as VP Pharma Partnerships, SaMD with a focus in the U.S. market. With over 15 years of experience in the pharmaceutical, medical device, and digital health industries, Paul has made significant contributions to these fields.

Paul began his career as a management consultant at Campbell Alliance (now Syneos Health), a global life science consulting firm. For four years, he supported pharma and medtech clients worldwide, leading several digital health initiatives.

Following Campbell Alliance, Paul co-founded Nurep, a digital health startup aimed at disrupting the $30B medical device sales rep market. Over five years, he took Nurep from concept to clinical validation, partnering with a large academic medical center and a leading medical device company while raising a significant seed round of funding from top early-stage investors.

After Nurep, Paul became an entrepreneur-in-residence at Stanford StartX Med, a startup accelerator affiliated with Stanford University. There, he supported the Med portfolio with strategic initiatives and partnerships.

Following Nurep, Paul became a VP of Biopharma Partnerships at BrightInsigh where he led major partnerships with Novo Nordisk, Roche, CSL-Behring, and Sanofi.

Paul holds a Master's in Business and Science from Keck Graduate Institute, a member of the Claremont Colleges, and a Bachelor of Science in Biotechnology from Washington State University.